<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836498</url>
  </required_header>
  <id_info>
    <org_study_id>V260-027</org_study_id>
    <secondary_id>2007_537</secondary_id>
    <nct_id>NCT00836498</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)</brief_title>
  <official_title>V260-027 Safety and Immunogenicity of RotaTeq™ in Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a Phase I clinical trial including 2 parts to evaluate the safety and immune response
      to RotaTeq™ /placebo in subjects of 65 to 80 years of age. In Part I, approximately 60
      subjects in US will be randomly assigned to 1 of 2 treatment groups receiving 3 doses of
      RotaTeq™ or placebo. In Part II, approximately 200 subjects internationally will be randomly
      assigned to 1 of 3 treatment groups. Part II will start after Part I data analysis is
      reviewed and approved by the FDA/CBER, the Safety Evaluation Committee (SEC) and other
      regulatory agencies. Duration for the entire study will be approximately 4 years.

      Note: As the result of a business decision by the Sponsor, the study did not proceed with
      Part II. Therefore, this report includes the results for Part I only.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Strategic business decision not to pursue indication due to lack of demonstrable medical need
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Number of Participants With Nonserious and Serious Adverse Experiences (AEs)</measure>
    <time_frame>Up to 42 days following any dose of RotaTeq™ or placebo</time_frame>
    <description>All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I: Number of Participants With Serious Adverse Experiences (SAEs)</measure>
    <time_frame>Up to 180 days following the third dose of RotaTeq™ or placebo</time_frame>
    <description>All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.
SAEs were followed by passive surveillance (in which either participants self reported or information was collected at participants' last visit) for 180 days following the final dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I: Geometric Mean Titers (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)</measure>
    <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
    <description>GMTs of serum anti-rotavirus IgA responses after 1, 2, or 3 doses of RotaTeq™ or placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Number of Participants With Nonserious Adverse Experiences</measure>
    <time_frame>Up to 42 days following any dose of RotaTeq™ and/or placebo</time_frame>
    <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Number of Participants With Serious Adverse Experiences</measure>
    <time_frame>Up to 180 days following the third dose of RotaTeq™ and/or placebo</time_frame>
    <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Geometric Mean Titer (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)</measure>
    <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3</time_frame>
    <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G1</measure>
    <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G2</measure>
    <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G3</measure>
    <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G4</measure>
    <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype P1A[8]</measure>
    <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Geometric Mean Titers (GMTs) of Serum Neutralizing Antibody (SNA) Responses to G1, G2, G3, G4, and P1A</measure>
    <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3</time_frame>
    <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Percentage of Participants With a &gt;=3-fold Rise From Baseline of Serum Anti-rotavirus IgA and SNA Responses to Rotavirus Serotypes G1, G2, G3, G4 and P1A</measure>
    <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3</time_frame>
    <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Rotavirus</condition>
  <arm_group>
    <arm_group_label>Part I, RotaTeq</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of RotaTeq</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part I, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II, RotaTeq</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of RotaTeq</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II, RotaTeq and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of RotaTeq and 2 doses of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II, placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 doses of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: RotaTeq</intervention_name>
    <description>Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
    <arm_group_label>Part I, RotaTeq</arm_group_label>
    <arm_group_label>Part II, RotaTeq</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
    <arm_group_label>Part I, placebo</arm_group_label>
    <arm_group_label>Part II, placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: RotaTeq + Placebo</intervention_name>
    <description>One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period</description>
    <arm_group_label>Part II, RotaTeq and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is 65 to 80 years of age with controlled chronic illness

          -  agrees to participate in the study by giving written informed consent and cognitively
             competent as assessed by Mini-Mental State Examination

          -  for Part I: subject is living independently outside any long-term care facilities; for
             Part II: subject is expected to be a resident in a long term care facility (LTCF)
             including nursing homes with the exception of hospice care

          -  can be adequately followed for safety via visit or phone

          -  subject's routine safety lab results are within specified ranges

          -  has negative test results for HIV, Hepatitis B, and Hepatitis C

        Exclusion Criteria:

          -  abdominal cancer/surgery within the past 6 months

          -  known or suspected immune diseases, e.g. diabetes

          -  any chronic or relapsing infections

          -  a fever at the time of immunization

          -  active vomiting or diarrhea at the time of immunization

          -  chronic diarrhea, irritable bowel syndrome, or inflammatory disease of intestinal or
             colon in the past 12 months

          -  subjects' spouses/cohabitants are not healthy or are immunocompromised; roommates in
             LTCFs are not healthy and/or do not agree to participate in the study

          -  cannot be adequately followed for safety via visit or phone

          -  any other clinically significant conditions that, in the investigators' opinion, would
             interfere with subject's participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Lawrence J, He S, Martin J, Schödel F, Ciarlet M, Murray AV. Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects. Hum Vaccin Immunother. 2014;10(8):2247-54. doi: 10.4161/hv.29107.</citation>
    <PMID>25424929</PMID>
  </results_reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2009</study_first_submitted>
  <study_first_submitted_qc>February 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <results_first_submitted>January 12, 2011</results_first_submitted>
  <results_first_submitted_qc>January 12, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2011</results_first_posted>
  <last_update_submitted>April 10, 2015</last_update_submitted>
  <last_update_submitted_qc>April 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment of participants occurred at 8 study sites in the United States.</recruitment_details>
      <pre_assignment_details>Part II was not conducted; no participants were recruited.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RotaTeq™</title>
          <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40">Participant who discontinued the study vaccination due to AE completed the 180-day safety follow-up.</participants>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RotaTeq™</title>
          <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Between 65 and 80 years.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part I: Number of Participants With Nonserious and Serious Adverse Experiences (AEs)</title>
        <description>All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.</description>
        <time_frame>Up to 42 days following any dose of RotaTeq™ or placebo</time_frame>
        <population>All randomized participants who received at least one dose of RotaTeq™ or placebo are included in the summaries.
Number of participants with one or more adverse experience.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Number of Participants With Nonserious and Serious Adverse Experiences (AEs)</title>
          <description>All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.</description>
          <population>All randomized participants who received at least one dose of RotaTeq™ or placebo are included in the summaries.
Number of participants with one or more adverse experience.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part I: Number of Participants With Serious Adverse Experiences (SAEs)</title>
        <description>All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.
SAEs were followed by passive surveillance (in which either participants self reported or information was collected at participants' last visit) for 180 days following the final dose.</description>
        <time_frame>Up to 180 days following the third dose of RotaTeq™ or placebo</time_frame>
        <population>All randomized participants who received at least one dose of RotaTeq™ or placebo are included in the summaries.
Number of participants with one or more adverse experience.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Number of Participants With Serious Adverse Experiences (SAEs)</title>
          <description>All randomized participants were contacted via telephone or in-center visit on Days 7, 14, 28, and 42 after each dose. Participants received a Vaccination Report Card (VRC) at each vaccination visit as well as instructions for recording AEs. Participants were also instructed to record potential acute gastroenteritis episodes (AGEs) that occurred within 42 days after any dose on the report card.
SAEs were followed by passive surveillance (in which either participants self reported or information was collected at participants' last visit) for 180 days following the final dose.</description>
          <population>All randomized participants who received at least one dose of RotaTeq™ or placebo are included in the summaries.
Number of participants with one or more adverse experience.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part I: Geometric Mean Titers (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)</title>
        <description>GMTs of serum anti-rotavirus IgA responses after 1, 2, or 3 doses of RotaTeq™ or placebo.</description>
        <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
        <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Geometric Mean Titers (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)</title>
          <description>GMTs of serum anti-rotavirus IgA responses after 1, 2, or 3 doses of RotaTeq™ or placebo.</description>
          <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination GMT (n=36 RotaTeq/ n=19 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679.6" lower_limit="464.5" upper_limit="994.2"/>
                    <measurement group_id="O2" value="578.4" lower_limit="361.1" upper_limit="926.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 1 GMT (n=28 RotaTeq/ n=16 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1026.8" lower_limit="621.6" upper_limit="1696.2"/>
                    <measurement group_id="O2" value="552.8" lower_limit="314.5" upper_limit="971.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 2 GMT (n=37 RotaTeq/ n=20 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1187.0" lower_limit="807.6" upper_limit="1744.5"/>
                    <measurement group_id="O2" value="657.7" lower_limit="404.9" upper_limit="1068.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 3 GMT (n=38 RotaTeq/ n=18 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1179.9" lower_limit="785.5" upper_limit="1772.2"/>
                    <measurement group_id="O2" value="578.5" lower_limit="349.0" upper_limit="959.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part II: Number of Participants With Nonserious Adverse Experiences</title>
        <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
        <time_frame>Up to 42 days following any dose of RotaTeq™ and/or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Number of Participants With Nonserious Adverse Experiences</title>
          <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part II: Number of Participants With Serious Adverse Experiences</title>
        <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
        <time_frame>Up to 180 days following the third dose of RotaTeq™ and/or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Number of Participants With Serious Adverse Experiences</title>
          <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G1</title>
        <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
        <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G1</title>
          <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination GMT (n=36 RotaTeq/ n=19 Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314.5" lower_limit="219.2" upper_limit="451.3"/>
                    <measurement group_id="O2" value="281.4" lower_limit="152.6" upper_limit="519.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 1 GMT (n=28 RotaTeq/ n=16 Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506.2" lower_limit="330.5" upper_limit="775.4"/>
                    <measurement group_id="O2" value="228.7" lower_limit="121.0" upper_limit="432.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 2 GMT (n=37 RotaTeq/ n=20 Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556.1" lower_limit="389.8" upper_limit="793.5"/>
                    <measurement group_id="O2" value="226.7" lower_limit="136.8" upper_limit="375.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 3 GMT (n=38 RotaTeq/ n=18 Placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="535.9" lower_limit="395.9" upper_limit="725.4"/>
                    <measurement group_id="O2" value="231.6" lower_limit="140.3" upper_limit="382.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G2</title>
        <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
        <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G2</title>
          <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination GMT (n= 36 RotaTeq/ n=19 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" lower_limit="43.6" upper_limit="90.5"/>
                    <measurement group_id="O2" value="68.2" lower_limit="40.6" upper_limit="114.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 1 GMT (n= 28 RotaTeq/ n=16 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123.4" lower_limit="81.4" upper_limit="187.2"/>
                    <measurement group_id="O2" value="56.3" lower_limit="34.5" upper_limit="92.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 2 GMT (n= 37 RotaTeq/ n=20 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.2" lower_limit="81.6" upper_limit="151.6"/>
                    <measurement group_id="O2" value="74.3" lower_limit="46.2" upper_limit="119.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 3 GMT (n= 38 RotaTeq/ n=18 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127.0" lower_limit="93.1" upper_limit="173.3"/>
                    <measurement group_id="O2" value="71.3" lower_limit="44.5" upper_limit="114.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part II: Geometric Mean Titer (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)</title>
        <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
        <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Geometric Mean Titer (GMT) of Serum Anti-rotavirus Immunoglobulin A (IgA)</title>
          <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G3</title>
        <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
        <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G3</title>
          <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination GMT (n= 36 RotaTeq/ n=19 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141.8" lower_limit="95.7" upper_limit="210.1"/>
                    <measurement group_id="O2" value="90.9" lower_limit="62.1" upper_limit="133.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 1 GMT (n= 28 RotaTeq/ n=16 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="404.6" lower_limit="230.6" upper_limit="710.0"/>
                    <measurement group_id="O2" value="94.5" lower_limit="59.4" upper_limit="150.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 2 GMT (n= 37 RotaTeq/ n=20 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.7" lower_limit="219.5" upper_limit="498.3"/>
                    <measurement group_id="O2" value="119.8" lower_limit="79.6" upper_limit="180.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 3 GMT (n= 38 RotaTeq/ n=18 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388.0" lower_limit="264.7" upper_limit="568.7"/>
                    <measurement group_id="O2" value="102.1" lower_limit="66.3" upper_limit="157.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G4</title>
        <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
        <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype G4</title>
          <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination GMT (n= 36 RotaTeq/ n=19 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.6" lower_limit="66.1" upper_limit="126.8"/>
                    <measurement group_id="O2" value="102.7" lower_limit="65.7" upper_limit="160.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 1 GMT (n= 28 RotaTeq/ n=16 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.2" lower_limit="128.5" upper_limit="308.6"/>
                    <measurement group_id="O2" value="93.1" lower_limit="55.4" upper_limit="156.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 2 GMT (n= 37 RotaTeq/ n=20 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.9" lower_limit="154.2" upper_limit="325.3"/>
                    <measurement group_id="O2" value="110.1" lower_limit="68.4" upper_limit="177.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 3 GMT (n= 3 RotaTeq/ n=18 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.7" lower_limit="162.9" upper_limit="301.7"/>
                    <measurement group_id="O2" value="106.9" lower_limit="64.2" upper_limit="178.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype P1A[8]</title>
        <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3 of RotaTeq™ or placebo</time_frame>
        <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part I: Geometric Mean Titer (GMT) of Serum Neutralizing Antibody (SNA) Response to Human Rotavirus Serotype P1A[8]</title>
          <population>All endpoints exclude protocol violators &amp; participants with invalid data based on laboratory determinations.
Analyses of endpoints based on a Per-protocol (PP) population: participants who received at least one dose study designed material and had at least one valid assay result within study specified time window &amp; were not protocol violators.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Vaccination GMT (n= 36 RotaTeq/ n=19 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="230.8" lower_limit="166.8" upper_limit="319.4"/>
                    <measurement group_id="O2" value="143.4" lower_limit="88.9" upper_limit="231.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 1 GMT (n= 28 RotaTeq/ n=16 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.4" lower_limit="219.8" upper_limit="427.0"/>
                    <measurement group_id="O2" value="126.1" lower_limit="78.7" upper_limit="202.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 2 GMT (n= 37 RotaTeq/ n=20 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375.6" lower_limit="278.4" upper_limit="506.6"/>
                    <measurement group_id="O2" value="154.0" lower_limit="98.0" upper_limit="241.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postdose 3 GMT (n= 38 RotaTeq/ n=18 placebo)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327.6" lower_limit="253.8" upper_limit="423.0"/>
                    <measurement group_id="O2" value="160.7" lower_limit="102.3" upper_limit="252.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Geometric Mean Titers (GMTs) of Serum Neutralizing Antibody (SNA) Responses to G1, G2, G3, G4, and P1A</title>
        <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
        <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Geometric Mean Titers (GMTs) of Serum Neutralizing Antibody (SNA) Responses to G1, G2, G3, G4, and P1A</title>
          <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part II: Percentage of Participants With a &gt;=3-fold Rise From Baseline of Serum Anti-rotavirus IgA and SNA Responses to Rotavirus Serotypes G1, G2, G3, G4 and P1A</title>
        <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
        <time_frame>Prior to Dose 1 and 28 to 42 days Postdose 1, 2, and 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>RotaTeq™</title>
            <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Part II: Percentage of Participants With a &gt;=3-fold Rise From Baseline of Serum Anti-rotavirus IgA and SNA Responses to Rotavirus Serotypes G1, G2, G3, G4 and P1A</title>
          <description>Part II was not conducted due to study termination; this report summarizes study results from Part I only.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RotaTeq™</title>
          <description>Three dose regimen of RotaTeq™. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Three dose regimen of matching placebo. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.2</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <description>Reported within the 43-180 days post vaccination 3</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <description>Reported within the 42-day period post vaccination 1</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.2</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President of Late Stage Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

